Vorasidenib in IDH1/2 -mutant low-grade gliomas: a prospective study on volumetric MRI and seizure outcome

BACKGROUND: The IDH1/2 inhibitor vorasidenib demonstrated efficacy in residual or recurrent grade 2 IDH1/2-mutant gliomas after surgery. However, there is lack of knowledge regarding factors predicting the probability of response. PATIENTS AND METHODS: We conducted a prospective single-centre study on 54 grade 2 IDH1/2-mutant astrocytomas and IDH1/2-mutant 1p/19q-codeleted oligodendrogliomas treated with vorasidenib. MRI response (2D and 3D) and seizure outcome were longitudinally assessed. Factors associated with response were explored using regression models. RESULTS: With a median follow-up of 17.5 months, vorasidenib induced progressive tumour shrinkage on MRI, with median volume reductions of - 12.2% at cycle 6, -27.8% at cycle 12, and -55.5% at cycle 18. Best volumetric response was CR in 1 patient, PR in 5, MR in 9, SD in 31 and PD in 7. The ORR (CR + PR + MR) was 28%. Eighteen patients who had focal grade 3 areas showed similar volumetric response and ORR. 9/12 (75%) patients with baseline seizures achieved ≥50% reduction or seizure freedom. MRI response correlated with early treatment initiation and early seizure reduction. Vorasidenib was generally well tolerated, with liver enzyme elevation being the main adverse event. CONCLUSIONS: Vorasidenib induced sustained tumour shrinkage and seizure control. Early treatment initiation and early seizure reduction were associated with MRI response.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2026-11-12
DOI
https://doi.org/10.1093/neuonc/noag282
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Vorasidenib in IDH1/2 -mutant low-grade gliomas: a prospective study on volumetric MRI and seizure outcome

Giulio Mengozzi, Luca Bertero, Paola Cassoni, Edoardo Pronello et al.
Neuro-Oncology
Glioma Diagnosis and Treatment
article

Vorasidenib in IDH1/2 -mutant low-grade gliomas: a prospective study on volumetric MRI and seizure outcome

Giulio Mengozzi, Luca Bertero, Paola Cassoni, Edoardo Pronello, Gianluca Nocera, Alberto Luigi Gallotti, Laura Leoni, Francesco Bruno, Giovanni Morana, Antonella Castellano, Diego Garbossa, Andrea Falini, Marco Conti Nibali, Alessia Andrea Ricci, Alessia Pellerino, Tommaso Sciortino, Fabio Cofano, Lorenzo Bello, Riccardo Soffietti, Roberta Rudà, Federico Ponzetto, Alessia Melis, Lorenzo Gabriel Gay, Francesca Scalvini, Marco Rossi
article en

Abstract

BACKGROUND: The IDH1/2 inhibitor vorasidenib demonstrated efficacy in residual or recurrent grade 2 IDH1/2-mutant gliomas after surgery. However, there is lack of knowledge regarding factors predicting the probability of response. PATIENTS AND METHODS: We conducted a prospective single-centre study on 54 grade 2 IDH1/2-mutant astrocytomas and IDH1/2-mutant 1p/19q-codeleted oligodendrogliomas treated with vorasidenib. MRI response (2D and 3D) and seizure outcome were longitudinally assessed. Factors associated with response were explored using regression models. RESULTS: With a median follow-up of 17.5 months, vorasidenib induced progressive tumour shrinkage on MRI, with median volume reductions of - 12.2% at cycle 6, -27.8% at cycle 12, and -55.5% at cycle 18. Best volumetric response was CR in 1 patient, PR in 5, MR in 9, SD in 31 and PD in 7. The ORR (CR + PR + MR) was 28%. Eighteen patients who had focal grade 3 areas showed similar volumetric response and ORR. 9/12 (75%) patients with baseline seizures achieved ≥50% reduction or seizure freedom. MRI response correlated with early treatment initiation and early seizure reduction. Vorasidenib was generally well tolerated, with liver enzyme elevation being the main adverse event. CONCLUSIONS: Vorasidenib induced sustained tumour shrinkage and seizure control. Early treatment initiation and early seizure reduction were associated with MRI response.

Neuro-Oncology
Vita-Salute San Raffaele University (IT), University of Milan (IT), Istituto Clinico Sant'Ambrogio (IT), IRCCS Ospedale Galeazzi - Sant'Ambrogio (IT), IRCCS Ospedale San Raffaele (IT), Candiolo Cancer Institute (IT), University of Turin (IT)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon